Ayush ministry allows sale of Patanjali's Coronil as immunity booster
After a week full of controversy, Patanjali's Coronil will finally be available in stores but only as an immunity booster.
The Ayush ministry on Wednesday permitted Patanjali to sell Coronil as long as it is advertised as an immunity booster and not a coronavirus 'cure'.
Yoga guru Ramdev’s Patanjali Ayurved also said there are no Ayush Ministry restrictions on selling Coronil, the drug the company recently launched as medicine for Covid-19 but is now calling it a product to “manage” the disease.
The Union ministry confirmed that Patanjali can sell the product but not as a cure for Covid-19.
“Ayush Ministry has only given permission to sell this particular formulation as an immunity booster and not as a medicinal cure for Covid-19,” it said.
At a press conference in Haridwar, Ramdev claimed the ministry has said that Patanjali did an “an appropriate job for Covid-19 management”.
“I want to tell people who want to try these medicines that there is no restriction on their sale now and they will be available in a kit everywhere in the country from today," he added, referring to Coronil and the two other products Patanjali is promoting together.
Ramdev said the Union ministry had asked him to use the term “Covid management” in place of “Covid treatment” and he is following the instruction.
The ayurvedic drug had received licensing from the Uttarakhand government, where Patanjali headquarters are located, to be sold as an immunity booster.
However, it ran into controversy after Patanjali founder and yoga guru Ramdev launched the drug and claimed it could cure coronavirus.
The Ayush ministry put a stop on the sale and promotion of Coronil and asked Patanjali to provide all documentation related to the drug and the studies conducted to test it.
Now, the Ayush ministry has lifted its ban, provided the drug as sold as an immunity booster.
Even while backtracking on the describing Coronil as “treatment” for Covid-19, Patanjali stuck to its claim that the drug's trial on mild to moderately ill patients was successful.
Its press note said the trial, conducted after the necessary approvals, showed 100 per cent recovery of patients within seven days.